AASraw is with synthesis and production ability from gram to mass order of Trastuzumab (CAS 180288-69-1), under CGMP regulation and trackable quality control system.
Trastuzumab powder is used in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 25%-30% of primary breast cancers.Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumorcells that overexpress HER2. It is a mediator of antibody dependent cellular cytotoxicity, in that the binding of the antibody to HER2 overexpressing cells leads to preferential cell death.
AASraw is with synthesis and production ability from gram to mass order of Formestane (CAS 566-48-3), under CGMP regulation and trackable quality control system.
Formestane oiwder was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. Formestane suppresses estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor. It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.
Lapatinib powder video I.Lapatinib powder basic Characters: Name: Lapatinib powder CAS: 231277-92-2 Molecular Formula: C29H26ClFN4O4S Molecular Weight: 581.05 Melt Point: 136-140°C Storage Temp: Refrigerator Color: White or off white Crystalline powder 1.Tykerb powder basic Characters. Name Tykerb Cas 231277-92-2 Molecular Formula C29H26CIFN4O4S Molecular Weight 581.05 Color White or off white Crystalline […]
AASraw is with synthesis and production ability from gram to mass order of Lapatinib powder (231277-92-2), under CGMP regulation and trackable quality control system.
lapatinib powder is a cancer medicine that interferes with the growth and spread of cancercells in the body. lapatinib powder is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines. In postmenopausal women, lapatinib powder is given in combination with a hormonal medicine called letrozole (Femara). In others, lapatinib powder is given together with a cancer medicine called capecitabine (Xeloda).